文献速递外周动脉疾病

EUCLID试验:外周动脉疾病患者截肢的病因与结局

Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial.
PubMed 文献 · J Vasc Surg · 2021-09-28

EUCLID试验随机纳入13,885例外周动脉疾病(PAD)患者,其中5,345例合并糖尿病,随访中位30个月。共398例(2.9%)发生至少一次下肢非创伤性截肢,总计511次(大截肢255次,小截肢256次)。截肢后结局均较差,且截肢驱动因素因糖尿病病史而异:糖尿病患者以感染为主,非糖尿病患者以缺血为主。

要点

  • 小截肢史是小截肢的最强独立预测因素(OR 7.29),糖尿病次之(OR 4.60)。
  • 大截肢与小截肢后的后续大截肢、肢体不良事件及心血管不良事件率相似。
  • 糖尿病患者截肢主要驱动为感染(58%),非糖尿病患者为缺血(15%感染)。

核心结论

  • 截肢后结局无论大或小截肢均较差,小截肢的预后重要性需更多关注。
  • PAD患者截肢驱动因素因糖尿病病史不同:糖尿病以感染为主,非糖尿病以缺血为主。
  • 建议截肢命名采用解剖描述,并消除「大」或「小」截肢术语。

研究设计与样本

  • EUCLID试验随机对照研究,纳入13,885例有症状PAD患者,其中5,345例合并糖尿病,随机接受替格瑞洛或氯吡格雷治疗并随访长期结局。
  • 截肢由研究者前瞻性报告,主要和促成驱动因素通过安全性数据裁定,包括感染、缺血或多因素病因。
  • 分析大截肢和小截肢后的结局,包括再截肢、主要不良肢体事件、不良心血管事件和死亡率,采用多变量逻辑回归识别小截肢独立预测因素。

主要发现

  • 398例(2.9%)患者发生至少一次下肢非创伤性截肢,共511次截肢(大截肢255次,小截肢256次),中位随访30个月。
  • 小截肢史是小截肢的最强独立预测因素(OR 7.29;95%CI 5.17-10.30;P < .001),糖尿病次之(OR 4.60;95%CI 3.16-6.69;P < .001)。
  • 小截肢与大截肢患者后续大截肢率(12.2% vs 13.6%)、主要不良肢体事件率(15.1% vs 14.9%)和主要不良心血管事件率(17.6% vs 16.3%)相似。
  • 缺血单独为截肢主要驱动因素(51%),感染单独(27%),多因素病因(22%);糖尿病患者中感染为最常见驱动因素(58%),非糖尿病患者中感染占15%。

关键数值与推荐

  • 小截肢史预测小截肢的OR为7.29(95%CI 5.17-10.30;P < .001)。
  • 糖尿病预测小截肢的OR为4.60(95%CI 3.16-6.69;P < .001)。
  • 截肢驱动因素分布:缺血51%,感染27%,多因素22%;糖尿病者感染58%,非糖尿病者感染15%。

临床怎么用

  • 临床应重视小截肢的预后意义,小截肢后患者再截肢及心血管事件风险与大截肢相似。
  • 对合并糖尿病的PAD患者,应加强感染预防和管理,因其为截肢主要驱动因素。
  • 对非糖尿病PAD患者,应重点优化缺血评估和治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Amputation remains a frequent and feared outcome in patients with peripheral artery disease (PAD). Although typically characterized as major or minor on the extent of tissue loss, the etiologies and outcomes after amputation by extent are not well-understood. In addition, emerging data suggest that the drivers and outcomes of amputation in patients with PAD may differ in those with and without diabetes mellitus (DM). METHODS: The EUCLID trial randomized 13,885 patients with symptomatic PAD, including 5345 with concomitant diabetes, to ticagrelor or clopidogrel and followed them for long-term outcomes. Amputations were prospectively reported by trial investigators. Their primary and contributing drivers were adjudicated using safety data, including infection, ischemia, or multifactorial etiologies. Outcomes following major and minor amputations were analyzed, including recurrent amputation, major adverse limb events, adverse cardiovascular events, and mortality. Multivariable logistic regression models were used to identify independent predictors of minor amputations. Analyses were performed overall and stratified by the presence or absence of DM at baseline. RESULTS: Of the patients randomized, 398 (2.9%) underwent at least one lower extremity nontraumatic amputation, for a total of 511 amputations (255 major and 256 minor) over a median of 30 months. A history of minor amputation was the strongest independent predictor for a subsequent minor amputation (odds ratio, 7.29; 95% confidence interval, 5.17-10.30; P < .001) followed by comorbid DM (odds ratio, 4.60; 95% confidence interval, 3.16-6.69; P < .001). Compared with patients who had a major amputation, those with a minor amputation had similar rates of subsequent major amputation (12.2% vs 13.6%), major adverse limb events (15.1% vs 14.9%), and major adverse cardiovascular events (17.6% vs 16.3%). Ischemia alone was the primary driver of amputation (51%), followed by infection alone (27%), and multifactorial etiologies (22%); however, infection was the most frequent driver in those with DM (58%) but not in those without DM (15%). CONCLUSIONS: Outcomes after amputation remain poor regardless of whether they are categorized as major or minor. The pattern of amputation drivers in PAD differs by history of DM, with infection being the dominant etiology in those with DM and ischemia in those without DM. Greater focus is needed on the prognostic importance of minor amputation and of the multifactorial etiologies of amputation in PAD. Nomenclature with anatomical description of amputations and eliminating terms "major" or "minor" would seem appropriate.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Govsyeyev N, Nehler MR, Low Wang CC, et al. Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial. J Vasc Surg. 2021. PMID: 34597783. doi:10.1016/j.jvs.2021.08.096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。